Table 2.

Baseline characteristics of 381 genotyped patients and comparisons for the main RA characteristics between patients homozygous for the TNF GGC haplotype and the other haplotypes carriers.

Characteristics	Baseline value All patients (N=380)	TNF haplotype * GGC homozygous (N=189)	Others TNF haplotypes (N=164)	P-value* (* GGC homozygous versus other)
Sex, % female/% male	78.2/21.8	79.4/20.6	76.8/23.2	0.66
Age, mean +/− SD years	54.0 +/− 11.2	54.5 +/− 11.4	53.4 +/− 11.1	0.34
Disease duration, mean weeks	140.7	142.7	139.3	0.83
MDAS, mean +/− SD (range)	5.9 +/− 1.0 (3.2 – 8.9)	5.9+/− 1.0 (3.2 – 8.9)	5.9+/− 1.0 (3.2 – 8.3)	0.87
No. of tender joints (1–28) +/− SD	13.2 +/− 6.5	13.2 +/− 6.5	13.3 +/− 6.4	0.93
No. of swollen joints (1–28) +/− SD	9.8 +/− 5.0	9.6+/− 5.2	10.3+/− 4.8	0.09
RF positivity, %	70.9	71.3	70.8	0.99
CRP, mean mg/liter (range)	26.5 (3.5 – 167.0)	25.9 (3.5 – 146.0)	28.3 (3.5 – 167.0)	0.34
ESR, mean mm/hour (range)	31.6 (2.0 – 98.0)	32.2 (2.0 – 95.0)	30.6 (2.0 – 90.0)	0.50
ADA + MTX +,%	47.9	43.4	51.2
ADA + other DMARDs	25.3	27.0	25.0
ADA alone	26.8	29.6	23.8

ADA= adalimumab

MDAS = Modified Disease Activity Score based on erythrocyte sedimentation rate and an evaluation of 28 joints

ESR = erythrocyte sedimentation rate

RF = rheumatoid factor

CRP = C-reactive protein

MTX = methotrexate treatment associated with

DMARD=disease-modifying antirheumatic drug

^*TNF haplotype (-238G, -308G and -857C